News Release PathoQuest Reiterates its Strategic Growth Plans by Appointing Daniel Spasic to the Board Daniel Spasic, a highly experienced lifescience business leader, has been appointed as a non-executive director to the board of PathoQuest. With over 25 years of...
News Release The updated ICH Q5A(R2) draft guidance has been released PathoQuest, a leader in the development and provision of Next Generation Sequencing (NGS) testing services for the biopharmaceutical industry, is excited to announce that the updated ICH Q5A(R2)...
Press Release PathoQuest Announce the Opening of its New U.S. Facility The Leading Experts in NGS Biosafety Testing and Characterization of Biopharmaceuticals Launch New Capabilities in the Critical U.S. Market Wayne, PA, and Paris, France – October 4, 2022 –...
Editorial A Podcast from Transgene: NGS-Based Biosafety Strategy for Breakthrough Virus-Based Immunotherapies Return to the list of news Transgene is a French biotech developing virus-based immunotherapies. There manufacturing processes deal with...
Press Release PathoQuest Appoints Rainer Metzger, Ph.D. as Chairman of the Board of Directors PARIS, FRANCE – September 1st, 2022 – PathoQuest, a pioneer of next-generation sequencing (NGS)-based testing solutions for the quality control of biologics, today...
Editorial They talk about us: Staying abreast of regulations with NGS-based viral safety for faster, safer and more ethical lot release of vaccines. Return to the list of news Sridhar Pennathur, Vice President, Analytical Development at Novavax, highlights the value...
